Pegcetacoplan for refractory paroxysmal nocturnal haemoglobinuria associated with the C5 genetic variant

Br J Haematol. 2022 Mar;196(6):e57-e60. doi: 10.1111/bjh.17963. Epub 2021 Nov 19.

Authors

Shinobu Tamura^{1

2}, Yoshikazu Hori^{1

2}, Takayuki Hiroi¹, Masaya Morimoto^{1

2}, Yusuke Yamashita¹, Toshiki Mushino^{1

2}, Takashi Sonoki¹

Affiliations

¹ Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
² Department of Hematology, Kinan Hospital, Tanabe, Japan.

PMID: 34796912
DOI: 10.1111/bjh.17963

No abstract available

Keywords: C5 genetic variant; eculizumab; paroxysmal nocturnal hemoglobinuria; pegcetacoplan; refractory.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Complement Inactivating Agents
Hemoglobinuria, Paroxysmal* / genetics
Humans
Peptides, Cyclic

Substances

Complement Inactivating Agents
Peptides, Cyclic
pegcetacoplan